

# CERTIFICATE OF ANALYSIS

\* FOR QUALITY ASSURANCE PURPOSES. NOT A MAINE COMPLIANCE CERTIFICATE.

**300MG UNFLAVORED TINCTURE (TINCTURE) // PRODUCED: APR 25, 2022**

**CLIENT: CASCO BAY HEMP // BATCH: PASSED**



**BATCH NO.:** 0440  
**MATRIX:** TINCTURE  
**DENSITY:** 0.9376 g/ml  
**SAMPLE ID:** NAL-220420-019  
**COLLECTED ON:** APR 20, 2022  
**RECEIVED ON:** APR 20, 2022  
**SAMPLE SIZE:** 1.5 ML  
**SAMPLED BY:** BENJAMIN WALTERS  
**RECEIVED BY:** KAYLIN KEITH

## CANNABINOID OVERVIEW

<b>CBD:</b>	<b>1.19 %</b>
<b>Δ<sup>8</sup>-THC:</b>	<b>0.00 %</b>
<b>TOTAL CANNABINOIDS:</b>	<b>1.19 %</b>

**BATCH RESULT: PASSED**

**POTENCY** PASS

## CAN.1: POTENCY & CANNABINOID PROFILE BY HPLC-UV PREPARATION: APR 21, 2022 // ANALYSIS: APR 21, 2022

ANALYTE	LIMIT	AMT	AMT	LOD/LOQ (mg/ml)	PASS/FAIL
CBC	< LOQ	< LOQ		0.100/0.500	N/A
CBCA	ND	ND		0.100/0.500	N/A
CBD	1.19 %	11.2 mg/ml		0.100/0.500	N/A
CBDA	ND	ND		0.100/0.500	N/A
CBDV	ND	ND		0.100/0.500	N/A
CBDVA	ND	ND		0.100/0.500	N/A
CBG	ND	ND		0.100/0.500	N/A
CBGA	ND	ND		0.100/0.500	N/A
CBL	ND	ND		0.100/0.500	N/A
CBLA	ND	ND		0.100/0.500	N/A
CBN	ND	ND		0.100/0.500	N/A

ANALYTE	LIMIT	AMT	AMT	LOD/LOQ (mg/ml)	PASS/FAIL
CBNA		ND	ND	0.100/0.500	N/A
Δ <sup>8</sup> -THC		ND	ND	0.100/0.500	N/A
Δ <sup>9</sup> -THC		ND	ND	0.100/0.500	N/A
Δ <sup>10</sup> -THC		ND	ND	0.100/0.500	N/A
EXO-THC		ND	ND	0.100/0.500	N/A
THCA		ND	ND	0.100/0.500	N/A
THCV		ND	ND	0.100/0.500	N/A
THCVA		ND	ND	0.100/0.500	N/A
TOTAL THC**		ND	ND		N/A
TOTAL CBD**		1.19 %	11.2 mg/ml		N/A

\*\* TOTAL CBD = (CBDA X 0.877) + CBD

\*\* TOTAL THC = (THCA X 0.877) + THC

Reported on an as received basis

1000 µg/g = 1 mg/g



**RESULTS CERTIFIED BY:**  
BARRY CHAFFIN  
COO, NOVA ANALYTIC LABS  
APR 25, 2022

**RESULTS CERTIFIED BY:**  
GREG NEWLAND  
CSO, NOVA ANALYTIC LABS  
APR 25, 2022

**RESULTS CERTIFIED BY:**  
CHRIS ALTOMARE  
CEO, NOVA ANALYTIC LABS  
APR 25, 2022

[https://lims.tagleaf.com/coa\\_/KjA86tm4v0](https://lims.tagleaf.com/coa_/KjA86tm4v0)

\* FOR QUALITY ASSURANCE PURPOSES. NOT A MAINE COMPLIANCE CERTIFICATE.

ALL TESTS WERE PERFORMED IN ACCORDANCE WITH THE RULES AND REGULATIONS SET FORTH IN THE MAINE ADULT USE PROGRAM. LABORATORY SAMPLING PROTOCOLS ARE GOVERNED BY THE OMP'S SAMPLING GUIDANCE DOCUMENTS. ALL INFORMATION PROVIDED BY THE CLIENT, INCLUDING SELF SAMPLING, MUST BE ACCURATE AND ADHERE TO THE SAME RULES AND REGULATIONS. HOWEVER, CLIENT PROVIDED INFORMATION, INCLUDING SAMPLING, IS ULTIMATELY THE RESPONSIBILITY OF THE PROVIDING LICENSEE, REGISTERED CAREGIVER, PATIENT OR THE LIKE AND FAILURE TO FOLLOW SAID PROTOCOLS COULD LEAD TO ERRONEOUS TEST RESULTS. NOTE: NOT ALL POTENTIAL AND/OR EXISTING HAZARDS WERE ANALYZED.

**END OF REPORT**